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ABSTRACT
Objective: To investigate the utility associated with subcuta-
neous infusion (deferoxamine) compared with once-daily
oral administration (deferasirox) of iron chelation therapy.
Methods: Interviews using the time trade-off technique were
used to estimate preferences (utility) for health states by
ﬁnding the point at which respondents were indifferent
between a longer but lower quality of life (QoL) and a shorter
time in full health. Participants (n = 110) were community-
based, 51% women, median age 35 years, from four regions
in Sydney, Australia. Respondents rated three health states
involving equal outcomes for people with thalassemia but
with different treatment modalities for iron chelation; an
“anchor state” describing a patient receiving iron chelation
without administration mode speciﬁed, anchor state plus iron
chelation via subcutaneous infusion, and anchor state plus
iron chelation through once-daily oral medication.
Results: On an interval scale between 0 (death) and 1 (full
health), median (interquartile range) utility of 0.80 (0.65–
0.95) for the anchor state, 0.66 (0.45–0.87) for subcu-
taneous infusion, and 0.93 (0.80–0.97) for once-daily oral
administration was obtained. The mean (median) difference
of 0.23 (0.27) between the two treatments was statistically
signiﬁcant (Wilcoxon-signed rank test, P < 0.001). Subcuta-
neous infusion was associated with a mean (median) utility
0.13 (0.14) lower than the anchor state (P < 0.001), and
once-daily oral treatment had a utility 0.10 (0.13) higher
(P < 0.001).
Conclusion: Community respondents associate oral admin-
istration of an iron chelator such as deferasirox with
enhanced QoL compared with subcutaneous treatment.
Assuming equal safety and efﬁcacy, QoL gains from once-
daily oral treatment compared with subcutaneous infusion
are signiﬁcant.
Keywords: administration route, iron chelation, quality of
life, time trade-off.
Introduction
The health-related quality of life (HRQoL) of patients
has become increasingly important when considering
options for individual patient care and in allocating
health-care resources between competing treatments.
Chronic iron overload is a major complication of
potentially lifesaving blood transfusions used in the
ongoing treatment of hematological conditions such as
the thalassemias, myelodysplastic syndrome, and
sickle cell disease. Excess iron is deposited in various
tissues of the body, particularly the liver, heart, and
endocrine organs [1]. Once the body’s storage capacity
is exceeded, free iron catalyzes the formation of highly
reactive hydroxyl radicals which lead to membrane
damage and denaturation of proteins. This process
leads to tissue damage and ultimately to signiﬁcant
morbidity and mortality.
The current standard of care for chronic iron over-
load is the subcutaneous administration of deferoxam-
ine, for 8 to 12 hours per day, 5 to 7 days a week. This
treatment regimen in some cases leads not only to poor
compliance, and hence a reduction in the extent of
effective iron chelation, but also to a reduction in
HRQoL.
Deferasirox, a recently developed treatment for
transfusional iron overload, is a once-daily oral
therapy [2,3]. Evidence to date indicates that this treat-
ment has equivalent efﬁcacy to subcutaneous defer-
oxamine [2]; however, little is known about the
comparative HRQoL impacts of these alternative
treatments. There has been a dearth of research explor-
ing the HRQoL impacts of iron overload treatments
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including the route of administration, although a pre-
liminary study using the Sickness Impact Proﬁle indi-
cated that route of administration affected patient-
perceived HRQoL [4].
The current study aimed to elicit the strength of
community preferences (utility) between the different
modes of administration where the current standard
treatment, deferoxamine (subcutaneous administra-
tion), was compared with the new once-daily oral
treatment, deferasirox.
Methods
A community sample of 120 individuals was asked to
participate in a time trade-off (TTO) exercise. The
participants of the study were registrants of a market
research ﬁrm and were systematically sampled from
four geographic regions across Sydney, Australia.
These regions represented a range of sociodemo-
graphic characteristics, and a balanced sample across
socioeconomic status, age, and sex was recruited.
Respondents received a fee of AUS$45 at the end of
each interview. Ethics approval for the study was not
required as the registrants were not patients, no inter-
ventions were involved, and they had previously con-
sented to occasional surveys.
At interview, each participant was presented with
standardized background information on iron over-
load and its treatment, together with short descrip-
tions (vignettes or scenarios) of three health states
for patients with thalassemia. These vignettes were
designed to be clinically and domestically realistic, and
easily understood. Each of the vignettes is presented in
Box 1, and can be summarized as follows: 1) an
anchor/base state that described a patient who has iron
chelation without describing the treatment itself; 2) the
anchor state plus iron chelation via a subcutaneous
infusion; and 3) the anchor state plus iron chelation via
a once-daily oral medication.
An iterative approach was used to develop the
vignettes. That is, draft vignettes were shown to hema-
tology clinical specialists and people currently treated
for thalassemia to ensure that the descriptions were
clinically accurate, reﬂected the experiences of the
target patient population, and accurately represented
the necessary dimensions of HRQoL. Consultation on
the content of those vignettes continued until consen-
sus was achieved between the researchers, clinicians,
and people with thalassemia.
Following standard TTO methodology [5,6], par-
ticipants were then asked systematically to make a
series of hypothetical trade-offs between living in each
of these health states for 10 years, or shorter periods in
“normal health.” At the point of indifference, where
the participant was unable to choose between 10 years
in the alternative health state and the period of normal
health on offer, the participant implicitly assigned
equivalent value to the alternatives offered. The
“quality” weight then assigned, known as the level of
“utility” in economic evaluation, is the ratio of the
time in normal health on offer to the time in the
alternative health state (10 years).
To avoid ordering bias, respondents were random-
ized to respond to either health state (2) or (3) imme-
diately after their response to the anchor state. These
health states were not labeled in terms of the iron
chelator included and differed only in their description
of the mode of treatment administration. The range of
possible utility values was a maximum of 1 for full
health and a minimum of 0 for death.
Five novice interviewers received a training for two
full days by an experienced “master” interviewer. This
involved theoretical background, up to eight training
interviews with administrative staff, observation of at
least 16 interviews and accompanying commentary by
the trainer. These initial 16 interviews were undertaken
with one interviewer observing. During the study,
quality control interviewer meetings were held after
every 20 to 25 interviews. Given that the TTO exercise
can be difﬁcult for some interviewees and limited rel-
evant data were available to assist with sample size
estimation, 16 initial interviews were conducted.
Investigators and interviewers reviewed each initial
case to identify potential difﬁculties participants
were having with understanding the TTO technique,
whether interviewers were consistent with their oral
presentation of vignettes and how they reached the
point of indifference, and that the content of the
vignettes was acceptable to participants. No anomalies
were revealed, so no changes were made to the
vignettes or procedures.
Based on the ﬁrst 16 interviews, the standard devia-
tion across the three vignettes ranged from 0.29 to
0.35. We then estimated that at least 100 complete
interviews would give sufﬁcient power to detect a
difference in mean utility scores of 0.1 where
alpha = 0.05, power = 80%. A 10% difference in
mean utility score was chosen because it was consid-
ered that this represented an important difference in
QoL [7]. As the primary objective of this study was
to compare individual respondents’ scores across the
two routes of administration, the nonparametric
Wilcoxon-signed rank test was used. With TTO, as
some respondents may have extreme points of view
and/or will not trade, this conservative nonparametric
procedure was preferred over the parametric paired
t-test equivalent. Differences in utility values between
demographic factors were explored with the Mann–
Whitney U-test (two groups) or Kruskal–Wallis test
(two or more groups). The possible effects of vignette
ordering bias were examined using the Mann–Whitney
U-test. All analyses were undertaken using spss
version 14 (SPSS Inc., Chicago, IL, USA).
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Box 1 Vignettes
Anchor health state
Jenny/Jack has thalassemia but is otherwise healthy. Her/His condition has been managed since childhood
by having blood transfusions every month.
At the end of each month, before the transfusions, Jenny/Jack feels a bit tired but she/he can do all the things
that her/his friends can do.
Jenny/Jack understands that the transfusions prevent some of the complications of thalassemia but result in
too much iron accumulating in her/his body. This can lead to heart problems, tiredness, infertility, liver
damage, diabetes and possibly a shorter life.
She/He gets regular and effective treatment to stop the iron accumulating. The treatment takes some iron out
of her/his body, so damage does not occur to cells and organs. This treatment must be taken regularly for
all of her/his life.
Subcutaneous desferrioxamine
Ann/Andrew has thalassemia but is otherwise healthy. Her/His condition has been managed since childhood
by having blood transfusions every month.
At the end of each month, before the transfusions, Ann/Andrew feels a bit tired but she/he can do all the
things that her/his friends can do.
Ann/Andrew understands that the transfusions prevent some of the complications of thalassemia but result
in too much iron accumulating in her/his body. This can lead to heart problems, tiredness, infertility, liver
damage, diabetes and possibly a shorter life.
She/He gets regular and effective treatment to stop the iron accumulating. The treatment takes some iron out
of her/his body, so damage does not occur to cells and organs. This treatment must be taken regularly for
all of her/his life.
To treat the iron overload, Ann/Andrew has a subcutaneous infusion on about 5 days of the week.
She/He is able to prepare the infusion, medicine and needle by herself/himself and has become quite good
at inserting it into her/his skin.
The medicine is delivered by a small battery powered pump.
The infusion takes about 8 to 12 hours and during this time the pump is strapped to her/his arm during the
day as she/he moves around or sits next to the bed at night.
She/He changes the place on her/his body where she/he inserts the needle on a regular basis, but often her/his
skin gets sore around where she/he has had the needle.
Oral Defarasirox
Betty/Bob has thalassemia but is otherwise healthy. Her/His condition has been managed since childhood by
having blood transfusions every month.
At the end of each month, before the transfusions, Betty/Bob feels a bit tired but she/he can do all the things
that her/his friends can do.
Betty/Bob understands that the transfusions prevent some of the complications of thalassemia but result in
too much iron accumulating in her/his body. This can lead to heart problems, tiredness, infertility, liver
damage, diabetes and possibly a shorter life.
She/He gets regular and effective treatment to stop the iron accumulating. The treatment takes some iron out
of her/his body, so damage does not occur to cells and organs. This treatment must be taken regularly for
all of her/his life.
To treat the iron overload, Betty/Bob takes a tablet once a day every day of the week. She/He takes this tablet
by dissolving it in a glass of water.
The dissolved tablet is tasteless, makes the water cloudy.
Betty/Bob has no problem drinking it.
Full Health
Carol/Ken is free from any major illnesses, does not need to take any medications and has full quality of life.
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Results
A total of 110 interviews were undertaken. About half
were female, with an approximately even age distribu-
tion between 20 years and 60 years, 52% were
married or de facto with children, 61% were in full-
time employment, 41% had a university education,
and there was an approximately even distribution
across income levels (Table 1). Of those who were
employed the most frequent areas of occupation
were information technology (15%), followed by
accounting/legal (13%), health/science ﬁelds (13%),
and sales/retail (12%).
As part of an interview quality control process in
the current study, each interviewee was observed for
evidence that they had misunderstood the TTO
process or provided illogical answers. No interviewees
exhibited substantial misunderstanding, therefore, all
data were included in the analysis.
The TTO exercise revealed a quite different distri-
bution of preferences for the three health states (Fig. 1)
and a mean (median) utility of 0.75 (0.80) for the
anchor state, 0.61 (0.66) for the subcutaneously
infused iron chelator, and 0.85 (0.93) for the once-
daily oral iron chelator (Fig. 2).
The mean (median) difference of 0.23 (0.27) in the
utility value for the two treatments was highly statis-
tically signiﬁcant (Wilcoxon-signed rank test,
P < 0.001). Treatment with the subcutaneously infused
agent was associated with a lower mean (median)
utility value, being 0.13 (0.14) below that for the
Table 1 Sample demographics and utility rating for each anchor state, subcutaneous infusion, and oral medication
n
Anchor state Subcutaneous infusion Oral medication
Median IQR Median IQR Median IQR
Age (year)
<30 24 0.80 0.75–0.95 0.68 0.46–0.76 0.93 0.80–0.95
31–40 37 0.80 0.65–0.95 0.58 0.50–0.90 0.90 0.80–0.95
41–50 25 0.75 0.60–0.95 0.50 0.25–0.80 0.90 0.85–0.95
>50 24 0.91 0.70–0.99 0.81 0.58–0.90 0.96 0.88–1.00
(c2 = 3.5, df = 3, P = 0.3) (c2 = 5.5, df = 3, P = 0.1) (c2 = 4.5, df = 3, P = 0.2)
Sex
Female 55 0.78 0.65–0.95 0.62 0.35–0.89 0.90 0.78–0.97
Male 55 0.85 0.65–0.95 0.67 0.50–0.85 0.95 0.83–0.98
(Z = -1.1, P = 0.3) (Z = -0.5, P = 0.6) (Z = -1.2, P = 0.2)
Employment status
In paid work 81 0.80 0.65–0.95 0.62 0.48–0.85 0.93 0.80–0.97
Not in paid work 29 0.80 0.65–0.95 0.70 0.35–0.90 0.90 0.80–0.95
(Z = -0.3, P = 0.8) (Z = -0.3, P = 0.7) (Z = -1.2, P = 0.2)
Marital status
Married/de facto 69 0.80 0.65–0.95 0.60 0.45–0.89 0.90 0.80–0.98
Single 41 0.80 0.73–0.95 0.70 0.50–0.80 0.93 0.80–0.95
(Z = -0.2, P = 0.9) (Z = -0.1, P = 0.9) (Z = -0.3, P = 0.7)
Education
TAFE 33 0.80 0.65–0.96 0.69 0.50–0.89 0.95 0.80–1.00
University 45 0.80 0.65–0.95 0.55 0.45–0.80 0.93 0.80–0.95
Year 11 or less 9 0.88 0.75–0.95 0.75 0.55–0.89 0.90 0.88–0.95
Year 12 23 0.80 0.65–0.95 0.73 0.30–0.90 0.93 0.85–0.95
(c2 = 0.3, df = 3, P = 1.0) (c2 = 1.7, df = 3, P = 0.6) (c2 = 1.6, df = 3, P = 0.7)
Income (AUS$)
20 20 0.80 0.55–0.94 0.70 0.33–0.85 0.89 0.66–0.95
20–39 21 0.80 0.75–0.89 0.55 0.35–0.85 0.90 0.85–0.95
40–59 31 0.85 0.60–0.99 0.75 0.45–0.90 0.95 0.80–1.00
60–79 21 0.73 0.65–0.90 0.58 0.50–0.70 0.90 0.80–0.95
90+ 17 0.90 0.75–0.95 0.80 0.50–0.85 0.95 0.88–0.95
(c2 = 2.7, df = 4, P = 0.3) (c2 = 2.6, df = 4, P = 0.6) (c2 = 6.0, df = 4, P = 0.2)
IQR, interquartile range;TAFE,Technical and Further Education.
Figure 1 Frequency distribution of respondents scores across the three
health states (0.0 = death equivalent health-related quality of life, 1.0 = full
health).
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anchor state (P < 0.001). In contrast, treatment with a
once-daily oral iron chelator had a mean (median)
utility value that was 0.10 (0.13) (P < 0.001) higher
than the anchor state. These results were consistent
across respondent subgroups according to age, sex,
employment status, income, and education (Table 1).
No systematic differences in utility scores were
observed when the order of vignette presentation was
considered. For subcutaneous treatment, the median
(interquartile range [IQR]) utility when the subcutane-
ous treatment vignettewas presented ﬁrst (median 0.65,
IQR 0.50–0.85, n = 51) was similar to that when the
oral treatment vignette was presented ﬁrst (median
0.67, IQR 0.38–0.89, n = 59, Mann–Whitney
U = 1418, P = 0.61). For oral treatment, the median
(IQR) utility when the subcutaneous treatment vignette
was presented ﬁrst (median 0.95, IQR 0.80–1.00,
n = 51) was similar to that when the oral treatment
vignette was presented ﬁrst (median 0.90, IQR 0.80–
0.95, n = 59, Mann–Whitney U = 1287, P = 0.19).
Conclusions
The study sought to estimate the strength of preference
society places on receiving treatment for iron overload
through a subcutaneous versus an oral administration
route. People from the general population were selected
to obtain a societal perspective rather than a patient-
speciﬁc perspective. These community-based prefer-
ences reﬂect “utility” values as applied in economic
evaluations and are more informative than patient-
based preferences when making judgments about the
allocation of societal resources within health care [5,6].
Although the applicability of community-based
preferences to decisions regarding patient treatment at
the individual patient level is limited, a recent review
highlighted that the mode of administration of iron
chelation therapy is perceived by patients with thalas-
semia as an important determinant of HRQoL [8].
Our results clearly show that community respondents
prefer the health state in which patients receive the
daily oral treatment compared with that where
patients receive subcutaneous treatment. The mean
difference was large: 0.23 (median 0.27) units. In QoL
research, a change of 10% of a scale is regarded as at
least a minimal important difference [7].
The mean utility value associated with the health
state in which the oral treatment (deferasirox) is used
was relatively high (mean 0.85), suggesting respon-
dents appear willing to only give up a median of
11 months of life out of 10 years. This implies that
most respondents regard having iron overload that is
treated by an oral daily treatment as still offering good
HRQoL. In contrast, having iron overload that is
treated with subcutaneous infusion on about 5 days of
the week is regarded as a suboptimal health state;
people are willing to give up about 3.5 years of life out
of 10 years to live in normal health.
Previous work undertaken to investigate a similar
question in the area of intravenous versus oral ganci-
clovir for maintenance treatment of AIDS-related
cytomegalovirus retinitis showed a signiﬁcant impact
of the route of drug administration on the utility value
that patients associate with treatment. In this study,
utility differences of greater than 0.3 units were
reported, slightly larger than what we observed in the
present study [9].
That a preference exists for oral therapy compared
with subcutaneous infusion is not surprising. This
study provides further conﬁrmation of the strength of
that preference. When compared with HRQoL studies
in other clinical contexts, the reduction in HRQoL in
our study of 0.23 from oral administration to subcu-
taneous infusion is similar to that reported from
normal health to angina and congestive heart failure
[10], less than 4 months post lung transplant [11], or
for an acute depressive episode [12].
In this study, we aimed to ensure the utilities
extracted by the TTO exercise resulted in consistent
and reliable data. In previous studies, acceptable reli-
ability data have been reported for the TTO technique
where intraclass correlation coefﬁcient estimates
ranged from 0.61 to 0.88 [13–15]. In the present study,
the widest range of preference scores was observed
for subcutaneous administration (Fig. 1), but a clear
pattern of higher utility was observed for the oral
route. As we presented only three TTO exercises to
each participant (anchor, intravenous, and oral), we
included a randomization procedure for the latter two
vignettes with the aim of reducing ordering effects and
potential for consequent systematic bias. The clear
differentiation between the latter two vignettes implies


























Figure 2 Mean and 95% conﬁdence intervals (CI) for utility values for
each health state (0.0 = death equivalent health-related quality of life,
1.0 = full health).
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responses to the subcutaneous infusion presumably
reﬂects wide community preferences for the QoL this
administration procedure confers.
A potential weakness of the study is the lack of
population-based sampling. The sample did include a
substantial number of respondents from higher socio-
economic backgrounds and it is unknown how other
population subgroups may have responded to the
vignettes. The study could have been improved
through the inclusion of cognitive debrieﬁng inter-
views to ratify respondent’s answers and inclusion of
formal test–retest studies to assess statistical reliability
of the TTO interviews.
Although this study incorporated a purposeful sam-
pling, rather than a more rigorous population-based
sampling approach, the consistency of the results
across the respondents suggests that they may be gen-
eralizable across members of the community. These
results indicate that society associates oral administra-
tion of an iron chelator with an advancement in the
HRQoL of patients who require such treatment.
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